News coverage about Neos Therapeutics (NASDAQ:NEOS) has trended positive this week, Accern Sentiment Analysis reports. The research firm identifies positive and negative news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neos Therapeutics earned a coverage optimism score of 0.38 on Accern’s scale. Accern also gave news stories about the company an impact score of 44.8544744494225 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
These are some of the media headlines that may have impacted Accern Sentiment’s scoring:
- Neos Therapeutics (NEOS) Releases Quarterly Earnings Results, Beats Estimates By $0.12 EPS (americanbankingnews.com)
- Neos Therapeutics (NEOS) Given a $20.00 Price Target at Cantor Fitzgerald (americanbankingnews.com)
- Neos Therapeutics, Inc. to Host Earnings Call (finance.yahoo.com)
- Neos Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results (finance.yahoo.com)
- Are Earnings Prospects Improving For Loss-Making Neos Therapeutics Inc’s (NASDAQ:NEOS)? (finance.yahoo.com)
Several research analysts have recently commented on the company. Cantor Fitzgerald set a $20.00 price target on Neos Therapeutics and gave the stock a “buy” rating in a report on Thursday. BidaskClub raised Neos Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, March 10th. BMO Capital Markets downgraded Neos Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 31st. Finally, Zacks Investment Research downgraded Neos Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 25th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. Neos Therapeutics presently has an average rating of “Hold” and an average target price of $14.00.
Neos Therapeutics (NASDAQ:NEOS) last posted its earnings results on Thursday, March 15th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.12. Neos Therapeutics had a negative return on equity of 551.26% and a negative net margin of 339.52%. The firm had revenue of $7.79 million during the quarter, compared to analysts’ expectations of $9.30 million. sell-side analysts expect that Neos Therapeutics will post -2.85 earnings per share for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by BBNS and is the sole property of of BBNS. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/17/favorable-press-coverage-somewhat-unlikely-to-impact-neos-therapeutics-neos-stock-price/1901664.html.
About Neos Therapeutics
Neos Therapeutics, Inc is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. Its segment is engaged in the development, manufacturing and commercialization of pharmaceuticals. It has utilized its platform to develop its product for the treatment of attention deficit hyperactivity disorder (ADHD).
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.